2022 World Conference on Lung Cancer (ePosters)-EP08.02-142. Effects of Afatinib on the Treatment and Prognosis of Brain Metastasis in Advanced EGFR Mutation (+) NSCLC

EP08.02-142. Effects of Afatinib on the Treatment and Prognosis of Brain Metastasis in Advanced EGFR Mutation (+) NSCLC

Pdf Summary

This study examined the effects of afatinib, a medication that inhibits certain proteins involved in cancer growth, on the treatment and prognosis of brain metastasis in patients with non-small cell lung cancer (NSCLC) who have a specific type of genetic mutation called EGFR mutation. The researchers conducted a retrospective analysis of data from 422 patients who were treated with afatinib between April 2007 and August 2021. The study found that afatinib had a positive impact on overall survival rates, with a median overall survival of 48.6 months and a 60-month overall survival rate of 42.3%. The drug also showed efficacy in delaying the occurrence of brain metastases. However, patients with brain metastases at the time of diagnosis had a lower overall survival rate compared to those without brain metastases. The study also reported the most common adverse events associated with afatinib treatment, including diarrhea, rash, and paronychia. The researchers concluded that further studies are needed to determine the optimal treatment approach for patients with lung cancer and brain metastases, including whether afatinib monotherapy or afatinib treatment after surgery or radiotherapy is more appropriate. Overall, the study suggests that afatinib may be an effective treatment option for NSCLC patients with EGFR mutation and brain metastasis, but more research is needed to determine the best treatment approach for this specific patient population.

Asset Subtitle

Sung Yong Lee

Meta Tag

Speaker Sung Yong Lee

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

afatinib

cancer growth

brain metastasis

non-small cell lung cancer

NSCLC

EGFR mutation

overall survival

brain metastases

adverse events

treatment approach